Consortium lead by Prophylix Pharma AS receives up to €6 M in EU-funding
The EU grant is for development of a prophylactic treatment to prevent severe bleeding and death in newborns caused by Fetal/Neonatal Alloimmune Trombocytopenia
09-May-2012 -
Prophylix Pharma AS announced that its project proposal for developing a new therapy to prevent Fetal/Neonatal Alloimmune Trombocytopenia (FNAIT) has been favorably evaluated by the EU Commission and will receive up to €6 million in funding under the Seventh Framework Programme (FP7-HEALTH). The ...